Intestinal Immunity of Escherichia coli Nissle 1917:Safe Vehicles for Targeted Therapeutics

摘要

The probiotics E.coli Nissle 1917 has been widely used in medicine and cattle production industry.Escherichia coli strain Nissle 1917 is a non-pathogenic fecal isolate,combining both the excellent colonization properties and its non-immunogenic character.and can be administrated orally.Genetically modified probiotics can very well be an ideal candidate as carrier organism for gut-focused in situ synthesis and expression of specific localized antigen delivery into the intestine.And for the first time,a live genetically modified bacterial strain has been approved by Dutch authorities as a therapeutic agent for experimental therapy of intestinal bowel disease (IBD)in humans.